Could a common clot drug fade stubborn skin darkening?
NCT ID NCT04233749
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This small phase 2 trial is testing whether tranexamic acid, a drug used to reduce bleeding, can lighten dark patches on the skin caused by lichen planus pigmentosus and erythema dyschromicum perstans. Five adults will take the drug twice daily for six months. Researchers will measure changes in pigmentation using special light devices.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tranexamic acid tablets
- What this could lead to
- If it works, this could offer a new treatment option for stubborn skin darkening conditions that currently have no effective therapy.
- What could go wrong
- This is a very small early-phase trial with only 5 participants, so results may not apply widely. Tranexamic acid also carries a risk of blood clots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASHY DERMATOSIS OF RAMIREZ are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
New Center One
RECRUITINGDetroit, Michigan, 48202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.